Further analysis suggested that this could be achieved by targeting hsa-miR-6758-3p/hsa-miR-3977/hsa-miR-6804-3p/hsamiR-1266-3p/hsa-miR-3620-3p and regulating their downstream mRNAs, such as VEGFB, HIF1A, platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) to promote angiogenesis in MM. Here, VEGFB is linked to Miyoshi myopathy.